<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38017564</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2523-3106</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Advances in rheumatology (London, England)</Title><ISOAbbreviation>Adv Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of influenza A(H3N2) component vaccine in juvenile systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>55</StartPage><MedlinePgn>55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s42358-023-00339-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Seasonal influenza A (H3N2) virus is an important cause of morbidity and mortality in the last 50 years in population that is greater than the impact of H1N1. Data assessing immunogenicity and safety of this virus component in juvenile systemic lupus erythematosus (JSLE) is lacking in the literature.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in JSLE.</AbstractText><AbstractText Label="METHODS">24 consecutive JSLE patients and 29 healthy controls (HC) were vaccinated with influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Influenza A (H3N2) seroprotection (SP), seroconversion (SC), geometric mean titers (GMT), factor increase in GMT (FI-GMT) titers were assessed before and 4 weeks post-vaccination. Disease activity, therapies and adverse events (AE) were also evaluated.</AbstractText><AbstractText Label="RESULTS">JSLE patients and controls were comparable in current age [14.5 (10.1-18.3) vs. 14 (9-18.4) years, p = 0.448] and female sex [21 (87.5%) vs. 19 (65.5%), p = 0.108]. Before vaccination, JSLE and HC had comparable SP rates [22 (91.7%) vs. 25 (86.2%), p = 0.678] and GMT titers [102.3 (95% CI 75.0-139.4) vs. 109.6 (95% CI 68.2-176.2), p = 0.231]. At D30, JSLE and HC had similar immune response, since no differences were observed in SP [24 (100%) vs. 28 (96.6%), p = 1.000)], SC [4 (16.7%) vs. 9 (31.0%), p = 0.338), GMT [162.3 (132.9-198.3) vs. 208.1 (150.5-287.8), p = 0.143] and factor increase in GMT [1.6 (1.2-2.1) vs. 1.9 (1.4-2.5), p = 0.574]. SLEDAI-2K scores [2 (0-17) vs. 2 (0-17), p = 0.765] and therapies remained stable throughout the study. Further analysis of possible factors influencing vaccine immune response among JSLE patients demonstrated similar GMT between patients with SLEDAI &lt; 4 compared to SLEDAI ≥ 4 (p = 0.713), as well as between patients with and without current use of prednisone (p = 0.420), azathioprine (p = 1.0), mycophenolate mofetil (p = 0.185), and methotrexate (p = 0.095). No serious AE were reported in both groups and most of them were asymptomatic (58.3% vs. 44.8%, p = 0.958). Local and systemic AE were alike in both groups (p &gt; 0.05).</AbstractText><AbstractText Label="CONCLUSION">This is the first study that identified adequate immune protection against H3N2-influenza strain with additional vaccine-induced increment of immune response and an adequate safety profile in JSLE. ( www.</AbstractText><AbstractText Label="CLINICALTRIALS">gov , NCT03540823).</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aikawa</LastName><ForeName>Nadia Emi</ForeName><Initials>NE</Initials><Identifier Source="ORCID">0000-0002-7585-4348</Identifier><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil. nadia.aikawa@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil. nadia.aikawa@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borba</LastName><ForeName>Eduardo Ferreira</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balbi</LastName><ForeName>Verena Andrade</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallum</LastName><ForeName>Adriana Maluf Elias</ForeName><Initials>AME</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buscatti</LastName><ForeName>Izabel Mantovani</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Lucia Maria Arruda</ForeName><Initials>LMA</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozu</LastName><ForeName>Kátia Tomie</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Cristiana Couto</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Laboratory of Respiratory, Exanthematic Viruses, Enterovirus and Viral Emergencies, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Research Group On Biomarkers. René Rachou Institute, FIOCRUZ Minas, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capão</LastName><ForeName>Artur Silva Vidal</ForeName><Initials>ASV</Initials><AffiliationInfo><Affiliation>Laboratory of Respiratory, Exanthematic Viruses, Enterovirus and Viral Emergencies, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Proença</LastName><ForeName>Adriana Coracini Tonacio</ForeName><Initials>ACT</Initials><AffiliationInfo><Affiliation>Department of Infectious and Parasitic Diseases, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>Elaine Pires</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva Duarte</LastName><ForeName>Alberto José</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Clinical Laboratory Division - Department of Pathology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Marta Heloisa</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Infectious and Parasitic Diseases, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Clovis Artur</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, 3Rd Floor, room 3190 - Cerqueira Cesar, São Paulo, SP, CEP 05403-010, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonfá</LastName><ForeName>Eloisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03540823</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2018/16162-3</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>2015/03756-4</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>2010/10749-0</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>303378/2022-0</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Agency><Country /></Grant><Grant><GrantID>304984/2020-5</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Agency><Country /></Grant><Grant><GrantID>305242/2019-9</GrantID><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Adv Rheumatol</MedlineTA><NlmUniqueID>101734172</NlmUniqueID><ISSNLinking>2523-3106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">H3N2</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>0</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38017564</ArticleId><ArticleId IdType="doi">10.1186/s42358-023-00339-7</ArticleId><ArticleId IdType="pii">10.1186/s42358-023-00339-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for diagnosis of influenza virus infections in humans. Viruses. 2016;8(4):96. https://doi.org/10.3390/v8040096 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8040096</ArticleId><ArticleId IdType="pubmed">27077877</ArticleId><ArticleId IdType="pmc">4848591</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvennoinen H, Huusko T, Vuorinen T, Heikkinen T. Comparative Burden of influenza A/H1N1, A/H3N2 and B infections in children treated as outpatients. Pediatr Infect Dis J. 2015;34(10):1081–5. https://doi.org/10.1097/INF.0000000000000814 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000814</ArticleId><ArticleId IdType="pubmed">26181897</ArticleId></ArticleIdList></Reference><Reference><Citation>Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Koné-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112–22. https://doi.org/10.1016/j.autrev.2011.08.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.08.010</ArticleId><ArticleId IdType="pubmed">21896342</ArticleId></ArticleIdList></Reference><Reference><Citation>Heijstek MW, OttdeBruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–12. https://doi.org/10.1136/ard.2011.150193 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2011.150193</ArticleId><ArticleId IdType="pubmed">21813547</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CA, Aikawa NE, Bonfa E. Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol. 2013;9(9):532–43. https://doi.org/10.1038/nrrheum.2013.95 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2013.95</ArticleId><ArticleId IdType="pubmed">23820860</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CA, Aikawa NE, Pereira RM, Campos LM. Management considerations for childhood-onset systemic lupus erythematosus patients and implications on therapy. Expert Rev Clin Immunol. 2016;12(3):301–13. https://doi.org/10.1586/1744666X.2016.1123621 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/1744666X.2016.1123621</ArticleId><ArticleId IdType="pubmed">26589476</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52. https://doi.org/10.1136/annrheumdis-2019-215882 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215882</ArticleId><ArticleId IdType="pubmed">31413005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasoto SG, Ribeiro AC, Bonfa E. Update on infections and vaccinations in systemic lupus erythematosus and Sjögren’s syndrome. Curr Opin Rheumatol. 2014;26(5):528–37. https://doi.org/10.1097/BOR.0000000000000084 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000084</ArticleId><ArticleId IdType="pubmed">25022358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen L, Nielsen S, Christensen AE, Pedersen FK, Trebbien R, Fischer TK, et al. Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study. Pediatr Rheumatol Online J. 2021;19(1):26. https://doi.org/10.1186/s12969-021-00518-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-021-00518-0</ArticleId><ArticleId IdType="pubmed">33712043</ArticleId><ArticleId IdType="pmc">7953767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 2011;30(3):208–11. https://doi.org/10.1097/INF.0b013e3181f7ce44 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181f7ce44</ArticleId><ArticleId IdType="pubmed">20861757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol. 2001;19(5):589–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11579723</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(7):1121–7. https://doi.org/10.1002/acr.21948 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21948</ArticleId><ArticleId IdType="pubmed">23818263</ArticleId></ArticleIdList></Reference><Reference><Citation>Jester BJ, Uyeki TM, Jernigan DB. Fifty years of influenza A(H3N2) following the pandemic of 1968. Am J Public Health. 2020;110(5):669–76. https://doi.org/10.2105/AJPH.2019.305557 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2019.305557</ArticleId><ArticleId IdType="pubmed">32267748</ArticleId><ArticleId IdType="pmc">7144439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa A, Pleschka S. Influenza H3N2 vaccines: recent challenges. Trends Microbiol. 2018;26(2):87–9. https://doi.org/10.1016/j.tim.2017.12.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2017.12.003</ArticleId><ArticleId IdType="pubmed">29268980</ArticleId></ArticleIdList></Reference><Reference><Citation>Capão A, Aguiar-Oliveira ML, Caetano BC, Neves TK, Resende PC, Almeida WAF, et al. Analysis of viral and host factors on immunogenicity of 2018, 2019, and 2020 southern hemisphere seasonal trivalent inactivated influenza vaccine in adults in Brazil. Viruses. 2022;14(8):1692. https://doi.org/10.3390/v14081692 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081692</ArticleId><ArticleId IdType="pubmed">36016313</ArticleId><ArticleId IdType="pmc">9413331</ArticleId></ArticleIdList></Reference><Reference><Citation>Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51. https://doi.org/10.1016/S1473-3099(16)00129-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)00129-8</ArticleId><ArticleId IdType="pubmed">27061888</ArticleId></ArticleIdList></Reference><Reference><Citation>Belongia EA, McLean HQ. Influenza vaccine effectiveness: defining the H3N2 problem. Clin Infect Dis. 2019;69(10):1817–23. https://doi.org/10.1093/cid/ciz411 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz411</ArticleId><ArticleId IdType="pubmed">31102401</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsun N, Angelova S, Trifonova I, Tzotcheva I, Mileva S, Voleva S, et al. Predominance of influenza A(H3N2) viruses during the 2016/2017 season in Bulgaria. J Med Microbiol. 2018;67(2):228–39. https://doi.org/10.1099/jmm.0.000668 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.000668</ArticleId><ArticleId IdType="pubmed">29297852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu SS, Kwan MYW, Feng S, Wong JSC, Leung CW, Chan ELY, et al. Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/2017. J Infect Dis. 2018;217(9):1365–71. https://doi.org/10.1093/infdis/jiy027 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy027</ArticleId><ArticleId IdType="pubmed">29346614</ArticleId><ArticleId IdType="pmc">5894077</ArticleId></ArticleIdList></Reference><Reference><Citation>- Yang JR, Hsu SZ, Kuo CY, Huang HY, Huang TY, Wang HC, et al. An epidemic surge of influenza A(H3N2) virus at the end of the 2016–2017 season in Taiwan with an increased viral genetic heterogeneity. J Clin Virol. 2018;99–100:15–21. https://doi.org/10.1016/j.jcv.2017.12.012 .</Citation></Reference><Reference><Citation>Claudino Formiga FF, Silva CA, Pedrosa TDN, Aikawa NE, Pasoto SG, Garcia CC, et al. Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: a distinct pattern of immunogenicity. Lupus. 2021;30(12):1915–22. https://doi.org/10.1177/09612033211040371 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211040371</ArticleId><ArticleId IdType="pubmed">34459317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725–1725. https://doi.org/10.1002/art.1780400928 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann L, Syedbasha M, Vogt D, Hollenstein Y, Hartmann J, Linnik JE, et al. An optimized hemagglutination inhibition (HI) assay to quantify influenza-specific antibody titers. J Vis Exp. 2017;130:55833. https://doi.org/10.3791/55833 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/55833</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006;65(7):913–8. https://doi.org/10.1136/ard.2005.043943 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.043943</ArticleId><ArticleId IdType="pubmed">16322083</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 2006;24(16):3217–23. https://doi.org/10.1016/j.vaccine.2006.01.028 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.01.028</ArticleId><ArticleId IdType="pubmed">16466833</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz FM, Anderson EJ, Bernstein DI, Harrison CJ, Pahud B, Anderson E, et al. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019;37(36):5161–70. https://doi.org/10.1016/j.vaccine.2019.07.085 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.085</ArticleId><ArticleId IdType="pubmed">31375440</ArticleId><ArticleId IdType="pmc">10494964</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002;29(12):2555–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12465151</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209. https://doi.org/10.1016/j.phrs.2015.08.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2015.08.003</ArticleId><ArticleId IdType="pubmed">26275795</ArticleId><ArticleId IdType="pmc">7129276</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology (Oxford). 2012;51(6):1061–9. https://doi.org/10.1093/rheumatology/ker427 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker427</ArticleId><ArticleId IdType="pubmed">22298793</ArticleId></ArticleIdList></Reference><Reference><Citation>Dell’Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine. 2012;30(5):936–40. https://doi.org/10.1016/j.vaccine.2011.11.083 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.083</ArticleId><ArticleId IdType="pubmed">22138210</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167–73. https://doi.org/10.3899/jrheum.110721 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110721</ArticleId><ArticleId IdType="pubmed">22089462</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Orsi A, Spanò F, Puppo F, Durando P, Icardi G, et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev. 2014;13(2):75–84. https://doi.org/10.1016/j.autrev.2013.07.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.07.007</ArticleId><ArticleId IdType="pubmed">24044940</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Orsi A, Spanò F, Faccio V, Puppo F, Durando P, et al. Vaccine-preventable infections in Systemic Lupus Erythematosus. Hum Vaccin Immunother. 2016;12(3):632–43. https://doi.org/10.1080/21645515.2015.1107685 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1107685</ArticleId><ArticleId IdType="pubmed">26750996</ArticleId><ArticleId IdType="pmc">4964666</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa NE, Trudes G, Campos LM, Pereira RM, Moraes JC, Ribeiro AC, et al. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus. 2013;22(13):1394–8. https://doi.org/10.1177/0961203313505926 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313505926</ArticleId><ArticleId IdType="pubmed">24076765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>